Medicare $50 GLP-1 Bridge price excludes many patients who already have diabetes or sleep apnea
Medicare's GLP-1 Bridge pilot offers some Part D enrollees Wegovy, Zepbound KwikPen or Foundayo for $50 a month for weight loss. KFF Health News reported that people with FDA-approved treatment conditions such as Type 2 diabetes or moderate to severe sleep apnea are steered back to regular Part D copays instead.
WASHINGTON - Medicare's GLP-1 Bridge pilot can cut the monthly price of certain weight-loss drugs to $50 for some Part D enrollees, but many people with serious related diagnoses do not get that price, NPR and KFF Health News reported.
The short-term demonstration covers Wegovy, the KwikPen form of Zepbound, and the oral drug Foundayo for weight loss and weight maintenance. Many beneficiaries with a body mass index of 35 or higher can qualify if prescribed. People with a BMI of 27 to 34 may qualify if they also have listed conditions such as prediabetes or cardiovascular disease. Prior authorization for Bridge goes through a CMS contractor system rather than the usual insurer channel.
The catch is in the fine print. Bridge's $50 price applies only when the drug is used solely for weight loss. If a patient already has a condition the Food and Drug Administration has approved GLP-1s to treat, such as Type 2 diabetes or moderate to severe obstructive sleep apnea, the person is routed back to the regular Part D plan. Those plans can still require prior authorization and copays of hundreds of dollars a month.
KFF estimated about 3.8 million enrollees meet Bridge eligibility on claims data, while about 5.9 million others have obesity or overweight plus conditions that keep them on Part D pricing. Jeff La Marca, 68, of Basking Ridge, New Jersey, told KFF Health News he was denied after his doctor applied. He has a BMI of 42, prior heart bypass surgery, prediabetes and severe sleep apnea. Juliette Cubanski of KFF said Bridge was built for people who cannot get GLP-1 coverage through Part D for weight loss alone.
A CMS spokesperson told KFF Health News that most prior authorization requests in the early weeks finished in under 12 hours and that thousands of eligible beneficiaries have reached pharmacies. The agency has not published a full cost estimate. Cubanski said that if a quarter of Bridge-eligible people stay on treatment for the full 18 months, Medicare costs could run about $3.3 billion.
Go Deeper
What is the Bridge program?
An 18-month Medicare pilot that can give some Part D members select GLP-1 weight-loss drugs for $50 a month to test whether coverage saves money later.
Which drugs are included?
Wegovy, Zepbound in the KwikPen formulation, and oral Foundayo, under the reported pilot rules.
Who is shut out of the $50 price?
People using GLP-1s for FDA-approved conditions such as Type 2 diabetes or moderate to severe obstructive sleep apnea. They stay on standard Part D cost sharing.
How big is that group?
KFF estimated about 5.9 million Medicare enrollees have obesity or overweight plus conditions that route them away from the Bridge price.
What should seniors do next?
Confirm BMI and diagnosis rules with a clinician, check Part D benefits, and ask whether Bridge or regular coverage applies before filling a costly prescription.
More health
health50+Scientists identify new tick-borne virus after testing thousands of patients in China
Chinese researchers identified Asian longhorned tick nairovirus in 10.4% of 3,163 patients bitten by ticks. The virus can cause flu-like illness, low
Sep 5
health50+Higher blood xylitol levels linked to greater heart attack and stroke risk in study
A study presented at the ESC Cardiology Congress followed more than 17,700 Canadian and British adults and linked higher blood xylitol levels to more
Sep 5
health50+WHO adds seven dementia risk factors including stroke, sleep problems and air pollution
The World Health Organization updated its dementia risk-reduction guidelines with seven added factors: stroke, traumatic brain injury, vision impairme
Sep 5